HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe

Briefly: Inogen to Announce Q2 Earnings; FDA Continues Monitoring Philips Respironics OLA+ Reports
Featuring Inogen, the U.S. Food & Drug Administration, and Philips Respironics.

July 18, 2024 by Laurie Watanabe

Inogen to Report Q2 Earnings on Aug. 6

Inogen (Nasdaq: INGN) will announce its second-quarter 2024 financial results in a conference call starting at 5 p.m. Eastern on Aug. 6.

Join the live conference call by dialing in as noted on Inogen’s website. An archived version of the conference call will be available on the investor relations website approximately three hours after the live event ends.


FDA Continues to Evaluate Reports on OLA+ Device Interruptions

The U.S. Food & Drug Administration (FDA) said in a July 16 announcement that it is “continuing its evaluation of the number of reports” associated with the Philips Respironics OmniLab Advanced + (OLA+) system.

In April, Philips sent OLA+ users an urgent medical device recall related to its Ventilator Inoperative Alarm. Philips has since updated instructions on using the OLA+ because of the alarm failure, “which can cause therapy interruption or loss,” the FDA announcement said. The recall is related to the instructions, not to the device itself.

Philips describes the OLA+ as a “full-featured, enhanced and robust titration system” with two CPAP modes, plus additional bi-level modes.

Related Articles Read More >

Disability & Language
Resources and guidance on disability terminology.
Sunrise Medical Acquires Wheel Manufacturer Spinergy
The Spinergy team will remain intact, the Nov. 2 announcement said.
A Closer Look: The Benefits of Expanded Prior Authorization
In an HME Business webinar, panelists examined what Medicare’s latest prior authorization moves mean for DME suppliers.
Briefly: Prior Authorization Now Expanded by 7 Codes; Medtrade Opens 2027 Registration
Featuring the Centers for Medicare & Medicaid Services and Medtrade.

Get the free newsletter

Home Healthcare Softare

Subscribe to HME Business for industry & product news, trends and resources.
HME Business Directory
HME Podcasts
HME Business
  • Mobility Management
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • About HME Business
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe